The coronavirus illness 2019 (COVID-19), caused by SARS-CoV-2, is a global health hazard. The recent detection of SARS-CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination has confirmed the presence of the virus in neural tissue. This finding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases. It is important to consider the COVID-19 outbreak in a neuroinvasiveness context and the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2.
Dr. Rohit Walia
Faculty Department of Cardiology Aiims Rishikesh
Dr. Rajesh Chawla
Senior Consultant, Institutes of Critical Care Respiratory and Sleep Medicine in Indraprastha Apollo Hospitals, New Delhi
Dr. KK Aggarwal
President Heart Care Foundation of India and Group Editor in Chief MEDtalks
